QCG
IART icon

Quadrant Capital Group’s Integra LifeSciences IART Stock Holding History

Quadrant Capital Group’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189 Sell
20
-384
-95% -$4.22K ﹤0.01% 2672
2025
Q4 		$5.02K Buy
404
+258
+177% +$3.43K ﹤0.01% 2376
2025
Q3 		$2.09K Buy
+146
New +$2K ﹤0.01% 2460
2025
Q2 		– Sell
-8,696
Closed -$191K – 1924
2025
Q1 		$191K Buy
8,696
+7,302
+524% +$172K 0.01% 1317
2024
Q4 		$31.6K Buy
1,394
+1,371
+5,961% +$29.9K ﹤0.01% 1672
2024
Q3 		$418 Sell
23
-85
-79% -$1.97K ﹤0.01% 2675
2024
Q2 		$3.15K Buy
108
+48
+80% +$1.42K ﹤0.01% 2401
2024
Q1 		$2.13K Sell
60
-124
-67% -$4.96K ﹤0.01% 2498
2023
Q4 		$8.01K Sell
184
-264
-59% -$10.4K ﹤0.01% 2142
2023
Q3 		$17.1K Sell
448
-251
-36% -$10.6K ﹤0.01% 1777
2023
Q2 		$28.8K Sell
699
-395
-36% -$19K ﹤0.01% 1531
2023
Q1 		$62.8K Buy
1,094
+11
+1% +$620 0.01% 1099
2022
Q4 		$60.7K Sell
1,083
-211
-16% -$10.7K 0.01% 1055
2022
Q3 		$55K Buy
1,294
+1,108
+596% +$56.8K 0.01% 993
2022
Q2 		$10K Buy
186
+7
+4% +$420 ﹤0.01% 1653
2022
Q1 		$12K Sell
179
-6
-3% -$395 ﹤0.01% 1559
2021
Q4 		$12K Hold
185
– – ﹤0.01% 1546
2021
Q3 		$13K Hold
185
– – ﹤0.01% 1455
2021
Q2 		$13K Buy
185
+12
+7% +$849 ﹤0.01% 1439
2021
Q1 		$12K Hold
173
– – ﹤0.01% 1419
2020
Q4 		$11K Sell
173
-23
-12% -$1.24K ﹤0.01% 1341
2020
Q3 		$9K Sell
196
-34
-15% -$1.62K ﹤0.01% 1277
2020
Q2 		$11K Sell
230
-643
-74% -$31.6K ﹤0.01% 1281
2020
Q1 		$40K Buy
873
+709
+432% +$37.2K 0.01% 975
2019
Q4 		$8K Sell
164
-392
-71% -$23.3K ﹤0.01% 1959
2019
Q3 		$31K Buy
556
+392
+239% +$23.4K ﹤0.01% 1422
2019
Q2 		$8K Sell
164
-482
-75% -$24.8K ﹤0.01% 1865
2019
Q1 		$34K Buy
646
+446
+223% +$22.7K 0.01% 1359
2018
Q4 		$5K Hold
200
– – ﹤0.01% 1639
2018
Q3 		$10K Hold
200
– – ﹤0.01% 1288
2018
Q2 		$10K Hold
200
– – ﹤0.01% 1257
2018
Q1 		$9K Buy
200
+126
+170% +$6.6K ﹤0.01% 1308
2017
Q4 		$2K Hold
74
– – ﹤0.01% 1784
2017
Q3 		$2K Buy
74
+36
+95% +$1.85K ﹤0.01% 1790
2017
Q2 		$0 Hold
38
– – ﹤0.01% 1939
2017
Q1 		$1K Hold
38
– – ﹤0.01% 1805
2016
Q4 		$1K Hold
38
– – ﹤0.01% 1707
2016
Q3 		$1K Hold
38
– – ﹤0.01% 1690
2016
Q2 		$1K Hold
38
– – ﹤0.01% 1662
2016
Q1 		$1K Buy
+38
New +$1.18K ﹤0.01% 1522

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Quadrant Capital Group's IART Position: Q1 2026 in Review

Quadrant Capital Group reduced its Integra LifeSciences (IART) stake by 95% in Q1 2026, selling an estimated $4.22K and leaving 20 shares worth $189. The position accounts for ﹤0.01% of the portfolio, ranked #2672.

Quadrant Capital Group first reported a position in IART in Q1 2016 and has held it in 40 quarters since. The position peaked at $191K in Q1 2025. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Quadrant Capital Group held 20 shares of Integra LifeSciences worth $189 as of Q1 2026.
  • Quadrant Capital Group sold 384 Integra LifeSciences shares in Q1 2026, an estimated $4.22K.
  • Integra LifeSciences made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2672 holding.
  • Quadrant Capital Group first reported a position in Integra LifeSciences in Q1 2016 and has held it in 40 quarters since.
  • Quadrant Capital Group's Integra LifeSciences position peaked at $191K in Q1 2025.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.